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Purpose: The objective of this research work was to prepare and evaluate the effect of 
Eudragit RS PO and Eudragit RL PO polymers on the physical property and release 
characteristics of carbamazepine matrix tablets. 
Methods: Matrix tablets containing carbamazepine were prepared with Eudragit
®
 RS PO 
alone as the rate-retarding polymer (coded batch series ‘A’) and also with a combination of 
Eudragit
®
 RS PO and RL PO (coded batch series ‘B’). The tablets were characterized for 
hardness as well as for carbamazepine release. The release data were subjected to different 
models in order to evaluate their release kinetics and mechanisms. 
Results: The hardness of batch series ‘A’ matrix tablet was >160 kg/cm
2
 while for batch 
series ‘B’, it was >170 kg/cm
2
. Carbamazepine tablets containing only Eudragit RS PO 
showed very slow release (less than 6% in 8 h) but when Eudragit RL PO was blended with 
Eudragit RS PO, the release rate improved significantly to 44% in 24 h (p < 0.05). Drug 
release mechanism was a complex mixture of diffusion and erosion. 
Conclusion: Carbamazepine matrix tablets of satisfactory hardness were produced. 
Furthermore, by blending Eudragit RS PO with Eudragit RL PO in the matrix, tablets of 
varying release characteristics can be prepared. 
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Introduction 
 
Biopharmaceutics Classification System 
(BCS) class II drugs exhibit low solubility and 
high permeability characteristics
1
. Their oral 
absorption is mostly governed by in vivo 
dissolution; the solubility and the dissolution 
rate are therefore key determinants for the 
oral bioavailability of these drugs. This implies 
that a small increase in the dissolution rate will 





Carbamazepine, a dibenzapine derivative with 
a structure resembling the tricyclic 
antidepressants
3
, an effective anti-epileptic 
drug, belongs to the BCS class II
4,5
, a feature 





. Due to poor water solubility, its 
absorption is dissolution rate-limited, which 
often results in irregular and delayed 
absorption
7
. Carbamazepine has a narrow 
therapeutic window and a large diurnal 
variation in plasma concentration is 
observed
8
. Conventional tablets need to be 
administered 3-4 times a day and a sustained 
release (SR) preparation decreases side 
effects (by elimination of the peaks and 
troughs in plasma drug concentration) and 




polymers, e.g., ethylcellulose and acrylates, 
which are capable of forming insoluble or 
skeleton matrices, have been widely used for 
controlled release of drugs due to their 
inertness and drug embedding ability. Liquid 
penetration into the matrix is the rate-
controlling step in such systems, unless 




Acrylic polymers are widely used as tablet 
coatings and as retardants of drug release in 
sustained released formulations
10
. The most 
interesting acrylic polymers are high 
permeable Eudragit
®
 RL and low permeable 
Eudragit
®
 RS, both of which are neutral co-
polymers of poly (ethylacrylate, methyl 
methacrylate) and trimethyl aminoethyl 
methacrylate chloride, and are insoluble in 
water and digestive juices; but they swell and 
are permeable, which means that drugs 
embedded in their matrices can be released 
by diffusion
11
. Therefore, the permeability of 
drug through Eudragit RS and/or RL is 
independent of the pH of the digestive tract. 
The degree of permeability depends on the 
relative proportion of quaternary ammonium 
groups in Eudragit. The proportion of 
functional quaternary ammonium groups in 
Eudragit RL and Eudragit RS is 10 and 5%, 
respectively
11
. Eudragit RL PO and RS PO 
are fine, white powders with a slight amine-
like odor. They are characteristically the same 
polymers as Eudragit RS and RL. 
 
The aim of this work was to prepare uncoated 
plastic matrix tablets containing 
carbamazepine as a model drug, and Eudragit 
RS PO and Eudragit RL PO as plastic matrix 
to retard drug release. Another objective of 
this work was to evaluate drug release data 
using various kinetic models in order to 
determine the mechanism of drug release. 
 
Materials and Methods 
 
Carbamazepine (BDH, UK) was a gift from 
Eskayef (SK+F) Bangladesh Limited. Eudragit 
RL PO and Eudragit RS PO (BASF, 
Germany), Ludipress LCE - a lactose-based 
direct compression excipient used for modified 
release formulations (BASF, Germany), 
magnesium stearate (BDH, UK), talc (BDH, 
UK), Aerosil (BASF, Germany) and all other 
solvents and chemicals used, were of reagent 
grade.  
 
Preparation of carbamazepine matrix 
tablets  
 
The carbamazepine matrix formulations were 
composed as shown in Table 1. Batch series 
‘A’ consisted of tablets made with Eudragit RS 
PO alone as the matrix while the matrix of 
batch series ‘B’ tablets comprised of both 
Eudragit RS PO and RL PO. The mixture (for 
20 tablets), in each case, was well mixed in a 
locally fabricated laboratory drum blending 
machine at 40 rpm for 10 min and then an 
equivalent amount of dry powder (808  
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Table 1: Composition of carbamazepine matrix tablets 
Batch code 
Ingredient (mg) 
A1 A2 A3 A4 A5 B1 B2 B3 B4 B5 B6 
Carbamazepine  400 400 400 400 400 400 400 400 400 400 400 
Ludipress LCE 0 50 100 150 200 200 200 200 200 200 200 
Eudragit RS PO 400 350 300 250 200 160 140 120 100 80 60 
Eudragit RL PO 0 0 0 0 0 40 60 80 100 120 140 
Talc 3 3 3 3 3 5 5 5 5 5 5 
Mg-stearate 3 3 3 3 3 3 3 3 3 3 3 
Aerosil 2 2 2 2 2 2 2 2 2 2 2 
Total weight (mg) 808 808 808 808 808 810 810 810 810 810 810 
 












) ± SD 
A1 193.92 ± 0.40  B1 169.76 ± 0.36 
A2 217.64 ± 0.34  B2 199.43 ± 0.37 
A3 176.53 ± 0.32  B3 216.14 ± 0.74 
A4 206.16 ± 0.16  B4 204.97 ± 0.27 
A5 161.57 ± 0.40  B5 197.83 ± 0.20 
- -  B6 178.73 ± 0.47 
 
SD = standard deviation (n=5); The difference in mean 
tablet hardness between batch series ‘A’ and batch series 
‘B’ was significant (p < 0.05), except for batches A2 and B3. 
 
 
mg/tablet for batch series ‘A’ and 810 
mg/tablet for batch series ‘B’) was 
compressed in a “Perkin-Elmer” laboratory 
hydraulic press fitted with a 13 mm flat-faced 
punch and die set. The compression force and 
compression time were 5 tons and 20 
seconds, respectively. Before compression, 
the die-punch was sufficiently lubricated with 
magnesium stearate powder. The tablets were 
kept in a calcium chloride desiccator until 
used. 
 




For each formulation, the hardness of 5 
tablets was determined using an electronic 
hardness tester (Erweka TBH 28, Germany). 
The mean crushing strength (hardness) was 
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In vitro release studies  
 
In vitro drug release studies of the matrix 
tablets were conducted using a six-station 
USP XXII type 1 apparatus (Electrolab TDT-
06, India) at 37°C (± 0.5°C) and 50 rpm speed 
in 1 L of distilled water as a dissolution 
medium. Six millilitre (6 ml) samples were 
taken by filtration at regular time intervals over 
a period of 480 minutes in the case of ‘A’ 
series matrix tablets and over period of 720 
min for ‘B’ series tablets. After each sampling, 
the volume of the dissolution medium was 
replenished with 6 ml of distilled water. The 
absorbance of the samples, after filtration, 
was measured with a single-beam 
spectrophotometer (Shimadzu UV-1200, 
Japan) at 288 nm and amount of drug 
computed. 
 
Mechanism of drug release  
 
To determine the mechanism of drug release 
from the formulations, the data were treated 
according to zero-order
12
 (cumulative amount 
of drug released vs time, Eq 1) and the 
Highuchi
13
 (cumulative percent of drug 
released vs square root of time, Eq 2) models. 
 
tkMM
t 00 += ……………………………(1) 
2
1
0 tkMM Ht += …………………………(2) 
 
where Mt is the cumulative amount of drug 
released at any time, t and M0 is the dose of 
the drug incorporated in the delivery system. 
k0 and kH are rate constants for zero-order and 
Higuchi models, respectively. 
 
The dissolution data were also fitted according 
to the well-known exponential equation of 
Peppas et al
15
 (Eq 3) which is often used to 















 is the fraction of drug released at  
time, t, k is the kinetic constant, and n is the 
diffusional exponent for drug release. The 
diffusional exponent, n, is dependent on the 
geometry of the device as well as the physical 
mechanism for release. The values of n for a 
cylindrical shaped device are < 0.43 or 0.43 
for Fickian release and 0.85 for case II or 
zero-order release in this model. For systems 
exhibiting case II transport, the dominant 
mechanism for drug transport is due to 
polymer matrix relaxation. The value of n > 
0.43 but < 0.85 is considered as anomalous 
transport (non-Fickian) and refers to the 
coupling of Fickian diffusion and polymer 
matrix relaxation. The value of n > 0.85 is 






Hardness of matrix tablets  
 
The hardness of batch series “A” matrix 
tablets of ranged from 161.57 to 217.64 
kg/cm
2
 (Table 2) with matrix tablets A2, 
having Ludipress LCE and Eudragit RS PO in 
the ratio 1:7 exhibiting the highest value. 
Similarly, the hardness batch series “B” matrix 
tablets were varied from 169.76 to 216.14 
kg/cm
2
. In this case, the highest hardness was 
recorded for matrix tablets B3 containing 
Eudragit RL PO and Eudragit RS PO in the 
ratio of 2:3. The difference between the mean 
tablet hardness of batch series ‘A’ and batch 
series ‘B’ was significant (p < 0.05), except for 
batches A2 and B3. 
 
Drug release from matrix tablets  
 
The cumulative release data for 
carbamazepine from batch series “A” matrix 
tablets show that less than 10% drug was 
released in 8 h (see Figure 1). However, 
addition of Eudragit RL PO to Eudragit RS PO 
(i.e., batch series “B”) enhanced release rates 
to as high as > 40% (Figure 2). Increase in 
Eudragit RL PO content up to 50% of the total 
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polymer matrix produce release rates that 
increased slowly and linearly (Figure 2) but 
this changed to a sudden and sharp rise in 
release rate when the proportion of Eudragit 
RL PO exceeded 50%. The release rate 
attained a value of approximately 45% in 12 h 
when Eudragit RL PO constituted 70% of the 
matrix. The release data obtained were fitted 
into various release kinetic models and the 




In view of the importance of carbamazepine in 
the treatment of epilepsy and trigeminal 
neuralgia, the preparation of a suitable 
sustained release dosage form would not only 
increase the efficacy of treatment and patient 
compliance but should also produce desirable 
blood concentrations and decrease the 
incidence of adverse effects. 
 
It is well established that the hardness of the 
tablet can markedly affect the release rate of 
drug
17
. Since Eudragit polymers have plastic 
deformation properties and a tendency to coat 
drug particles, high compression forces result 
in hard tablets with low porosities. But at high 
compression forces, a continuous matrix is 
formed and the change in tablet hardness 
causes relatively small changes in porosity 
and, therefore, release rate
18
. A similar result 





Carbamazepine release from the Eudragit RS 
PO matrix tablets (batch series A) was very 
poor. This is attributable to the fact that 
carbamazepine is very poorly soluble drug in 
the dissolution medium
6
. Another reason is 
the fact that Eudragit RS PO is water insoluble 
and also has very low permeability
11
. Since 
this formulation did not contain any channeling 
agents, formation of pores and cracks did not 
occur to facilitate drug release. 
 
Release kinetics and mechanism of 
carbamazepine tablets containing Eudragit 
RS PO  
 
An ideal matrix formulation should contain 
polymers and diluents at amounts as little as 
possible, as well as releasing its content in a 
sustained release profile over a reasonable 
length of time, preferably with zero-order 
kinetics
19
. Carbamazepine release kinetics 
was determined by multiple coefficients (R
2
) 
for individual formulation (Table 3). From the 
correlation coefficient values, it appears that 
carbamazepine release mechanism from 
formula ‘A’ was mainly zero-order since it had 
a higher “R
2
” value for the whole release 
process. The zero-order rate describes 
systems where drug release rate is 




The diffusional exponent (see Table 3) of 
batches A1 and A2 imply that the release of 
carbamazepine was case II or zero-order 
transport. For systems exhibiting case II 
transport, the dominant mechanism for drug 
transport is due to polymer matrix relaxation. 
The diffusional exponent of batches A3, A4 
and A5 indicates non-Fickian type of release 
mechanism, meaning that drug release 
couples Fickian diffusion with polymer matrix 
relaxation - so-called anomalous diffusion - 
and may indicate that drug release is 
controlled by more than one process. 
 
Release kinetics and mechanism of 
carbamazepine tablets containing Eudragit 
RS PO and Eudragit RL PO 
 
As Figure 1 shows, the release of drug 
increased with increase in the proportion of 
Eudragit RL PO which also translates to a 
corresponding decrease in the proportion of 
Eudragit RS PO. This was due to the increase 
in solubility of the drug as a result of the 
presence of a more hydrophilic carrier 
surrounding the drug particles. 
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A1 0.906 0.005 0.979 0.123 0.8489 
A2 0.995 0.008 0.967 0.194 0.8478 
A3 0.985 0.009 0.947 0.218 0.6947 
A4 0.994 0.010 0.972 0.236 0.7923 
A5 0.995 0.011 0.969 0.262 0.7645 
B1 0.959 0.011 0.996 0.332 0.8359 
B2 0.959 0.011 0.997 0.349 0.7808 
B3 0.975 0.014 0.966 0.408 0.7282 
B4 0.974 0.015 0.947 0.430 0.7806 
B5 0.922 0.033 0.800 0.993 0.8682 
B6 
 
0.889 0.057 0.743 1.574 0.9169 
 

































Figure 1: Comparative release profile of carbamazepine from batches A1 (……), A2 (……),   A3 
(……), A4 (……), A5 (……).  X = Zero-order plot; Y = Higuchi plot.  Ratio of Ludipress LCE : Eudragit 
RS PO was: A1 (0:1), A2 (1:7), A3 (1:3), A4 (3:5), A5 (1:1). 
X 
Y 
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Figure 2: Comparative release profile of carbamazepine from batches B1 (……), B2 (……),   B3 
(……), B4 (……), B5 (……), B6 (……).  X = Zero-order plot, Y = Higuchi plot.  Ratio of Eurdagit RL 
PO : Eudragit RS PO is: B1 (1:4), B2 (3:7), B3 (2:3), B4 (1:1), B5 (3:2), B6 (7:3).                                      
 
 
From the correlation coefficient values (shown 
in Table 3), it appears that the Higuchi model 
seems the best-fitting model, which indicates 
a diffusion-controlled release. The erosion of 
the matrix tablet might have occurred due to 
the lower water solubility of the drug
20
, thus 
gradually reducing the diffusion path length, 
which in turn attenuates the decrease of the 
release rate in the Higuchi model, making the 
pattern to resemble zero-order model. 
 
Burst release of carbamazepine occurred in 
B6 formula. This can be attributed to the 
hydrophilic nature of Eudragit RL PO. When 
exposed to the dissolution medium, the 
solvent penetrates into the free spaces 
between macromolecular chains of Eudragit 
RL PO. After solvation of the polymer chains, 
the dimensions of the polymer molecule 
increase due to polymer relaxation by the 
stress of the penetrated solvent. 
 
The diffusional exponent (see Table 3) of 
batches B1 and B5 imply that release of 
carbamazepine was case II or zero-order 
transport. For systems exhibiting case II 
transport, the dominant mechanism for drug 
transport is due to polymer matrix relaxation. 
The diffusional exponent of batches B2, B3 
and B4 indicates non-Fickian type of release 
mechanism i.e., drug release is by coupling of 
Fickian diffusion and polymer matrix relaxation 
- so-called anomalous diffusion - and may 
indicate that drug release is controlled by 
more than one process. The diffusional 
exponent of batch B6 (0.9196) indicates super 
case II transport. In super case II transport, 
the release curve is linear for an exponential 
function of the release versus time. The higher 
drug release rate of Eudragit RS PO and 
Eudragit RL PO combination matrix tablets 
(batch series ‘B’), compared to drug release 
from Eudragit RS PO matrix tablets (batch 
series ‘A’), may be attributed to the higher 
hydrophilic groups in Eudragit RL PO 
molecules, creating pores and channels and 
thus facilitating solvent penetration and 
elevation of drug release. 
 
The carbamazepine matrix tablets did not 
fulfill the USP requirement for carbamazepine 
SR (sustained release) tablets, as it requires 
between 65% and 90% of the drug to be 
dissolved within 12 hours
21
. Pharmaceutical 
excipients can be used to improve drug 
solubility through various mechanisms, 
ranging from changing the pH in the 
microscopic environment surrounding drug 
particles, through affecting the physical state 
of drug molecules packed with each other, 
X Y 
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facilitating wetting by intestinal fluid, to 








Eudragit RS PO and Eudragit RL PO have 
potentials for aiding the formulation of 
sustained-release carbamazepine matrix 
tablets. In most cases, the release kinetics of 
carbamazepine from the matrix tablets 
appeared to follow zero-order release kinetics. 
Insensitivity of the release profile to moderate 
changes in hardness should be of great 
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